Related Experiment Video
Updated: Aug 23, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Immuno-PET: Design options and clinical proof-of-concept
Alexandre Lugat1, Clément Bailly1,2, Michel Chérel1,3
1Nantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, France.
Abstract:
Radioimmunoconjugates have been used for over 30 years in nuclear medicine applications. In the last few years, advances in cancer biology knowledge have led to the identification of new molecular targets specific to certain patient subgroups. The use of these targets in targeted therapies approaches has allowed the developments of specifically tailored therapeutics for patients. As consequence of the PET-imaging progresses, nuclear medicine has developed powerful imaging tools, based on monoclonal antibodies, to in vivo characterization of these tumor biomarkers. This imaging modality known as immuno-positron emission tomography (immuno-PET) is currently in fastest-growing and its medical value lies in its ability to give a non-invasive method to assess the in vivo target expression and distribution and provide key-information on the tumor targeting. Currently, immuno-PET presents promising probes for different nuclear medicine topics as staging/stratification tool, theranostic approaches or predictive/prognostic biomarkers. To develop a radiopharmaceutical drug that can be used in immuno-PET approach, it is necessary to find the best compromise between the isotope choice and the immunologic structure (full monoclonal antibody or derivatives). Through some clinical applications, this paper review aims to discuss the most important aspects of the isotope choice and the usable proteic structure that can be used to meet the clinical needs.
Insights
Nuclear medicine utilizes radioimmunoconjugates for targeted therapies. Immuno-positron emission tomography (immuno-PET) advances cancer imaging by assessing tumor biomarkers non-invasively.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Science
Background:
- Radioimmunoconjugates have a long history in nuclear medicine.
- Recent advances in cancer biology have identified new molecular targets for tailored therapies.
- Immuno-positron emission tomography (immuno-PET) has emerged as a powerful tool for in vivo characterization of tumor biomarkers.
Purpose of the Study:
- To review the critical aspects of isotope selection and protein structure for developing effective immuno-PET radiopharmaceuticals.
- To discuss the clinical applications and evolving role of immuno-PET in oncology.
Main Methods:
- Review of existing literature and clinical applications of radioimmunoconjugates and immuno-PET.
- Discussion on the selection criteria for isotopes and immunologic structures (monoclonal antibodies or derivatives).
Main Results:
- Immuno-PET offers non-invasive assessment of in vivo target expression and distribution, crucial for tumor targeting.
- Immuno-PET shows promise as a staging/stratification tool, for theranostic approaches, and as predictive/prognostic biomarkers.
- The development of immuno-PET drugs requires balancing isotope properties with the choice of immunologic targeting agents.
Conclusions:
- Immuno-PET is a rapidly growing field with significant medical value in oncology.
- Optimizing radiopharmaceutical design through careful isotope and immunologic structure selection is key to meeting clinical needs.
- This review highlights the importance of these considerations for advancing targeted cancer therapies and diagnostics.
